View More View Less
  • 1 Pécsi Tudományegyetem, Általános Orvostudományi Kar, Pécs
  • 2 Pécsi Tudományegyetem, Általános Orvostudományi Kar, Pécs, Rét utca 2., 7623
  • 3 MTA–PTE Klinikai Idegtudományi Képalkotó Kutatócsoport, Pécs
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Absztrakt

Az összefoglaló közleményben a szerzők részletesen bemutatják a Parkinson-kórhoz társuló neurokognitív zavarok jellegzetességeit, felmérésük lehetséges módjait és kezelési lehetőségeit. A neurokognitív zavarok meghatározását sokáig nehezítette a diagnosztikai kritériumrendszerek sokszínűsége. Az Amerikai Pszichiátriai Társaság által a Mentális Rendellenességek Kórmeghatározó és Statisztikai Kézikönyvének ötödik átdolgozása (Diagnostic and Statistical Manual of Mental Disorders, DSM-5) magával hozta a major és az enyhe neurokognitív zavar megnevezéseket a demencia és az enyhe kognitív zavar fogalmát helyettesítendően. A DSM-5 neurokognitív zavarra vonatkozó definíciói a klinikumban jól alkalmazhatóak, ám szükségessé vált a leggyakrabban használt szűrőtesztek, úgymint a Mini-Mentál Státus Vizsgálat, az Addenbrooke Kognitív Vizsgálat, a Montreal Kognitív Felmérés és a Mattis Demencia Pontozó Skála új kritériumrendszerhez való adaptálása. Magyar Parkinson-kóros populáción végzett validálási vizsgálatok alapján a minor neurokognitív zavarra vonatkozóan a legjobb diszkriminációs képességgel rendelkező határértékek az iskolázottság mértékétől függően változnak (Addenbrooke Kognitív Vizsgálat: 0–8 év iskolázottság esetén: 82,5, 9–12 év esetén: 83,5, ≥13 év esetén: 84,5 pont; Mini-Mentál Státus Vizsgálat: 26,5–27,5–28,5 pont; Montreal Kognitív Felmérés: 23,5–24,5–24,5 pont; Mattis Demencia Pontozó Skála: 138,5–139,5–139,5 pont). Orv. Hetil., 2015, 156(23), 915–926.

  • 1

    Leroi, I., McDonald, K., Pantula, H., et al.: Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J. Geriatr. Psychiatry Neurol., 2012, 25(4), 208–214.

  • 2

    Kovács, N.: Parkinson’s disease from the perspective of general practice. [A Parkinson-kór a gyakorló orvosok szemszögéből.] Lege Artis Medicinae, 2014, 24(8–9), 406–414. [Hungarian]

  • 3

    Yarnall, A. J., Breen, D. P., Duncan, G. W., et al.: Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology, 2014, 82(4), 308–316.

  • 4

    Pfeiffer, H. C., Løkkegaard, A., Zoetmulder, M., et al.: Cognitive impairment in early-stage non-demented Parkinson’s disease patients. Acta Neurol. Scand., 2014, 129(5), 307–318.

  • 5

    Halliday, G. M., Leverenz, J. B., Schneider, J. S., et al.: The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov. Disord., 2014, 29(5), 634–650.

  • 6

    Poletti, M., Emre, M., Bonuccelli, U.: Mild cognitive impairment and cognitive reserve in Parkinson’s disease. Parkinsonism Relat. Disord., 2011, 17(8), 579–586.

  • 7

    Godefroy, O., Azouvi, P., Robert, P., et al.: Dysexecutive syndrome: diagnostic criteria and validation study. Ann. Neurol., 2010, 68(6), 855–864.

  • 8

    Karádi, K., Lucza, T., Aschermann, Z., et al.: Visuospatial impairment in Parkinson’s disease: the role of laterality. Laterality, 2015, 20(1), 112–127.

  • 9

    Sanyal, J., Banerjee, T. K., Rao, V. R.: Dementia and cognitive impairment in patients with Parkinson’s disease from India: a 7-year prospective study. Am. J. Alzheimers Dis. Other Demen., 2014, 29(7), 630–636.

  • 10

    Reid, W. G., Hely, M. A., Morris, J. G., et al.: Dementia in Parkinson’s disease: a 20-year neuropsychological study (Sydney Multicentre Study). J. Neurol. Neurosurg. Psychiatry, 2011, 82(9), 1033–1037.

  • 11

    Balzer-Geldsetzer, M., Costa, A. S., Kronenbürger, M., et al.: Parkinson’s disease and dementia: a longitudinal study (DEMPARK). Neuroepidemiology, 2011, 37(3–4), 168–176.

  • 12

    Marder, K.: Cognitive impairment and dementia in Parkinson’s disease. Mov. Disord., 2010, 25(Suppl. 1), S110–S116.

  • 13

    Aarsland, D., Andersen, K., Larsen, J. P., et al.: Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol., 2003, 60(3), 387–392.

  • 14

    Martínez-Horta, S., Kulisevsky, J.: Is all cognitive impairment in Parkinson’s disease “mild cognitive impairment”? J. Neural. Transm., 2011, 118(8), 1185–1190.

  • 15

    Janvin, C. C., Larsen, J. P., Aarsland, D., et al.: Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov. Disord., 2006, 21(9), 1343–1349.

  • 16

    Palavra, N. C., Naismith, S. L., Lewis, S. J.: Mild cognitive impairment in Parkinson’s disease: a review of current concepts. Neurol. Res. Int., 2013, 2013, 576091.

  • 17

    Kovács, N., Balás, I., Llumiguano, C., et al.: Deep brain stimulation: a novel possibility for the treatment of movement disorders. [Mély agyi stimuláció: új perspektíva a mozgászavarok kezelésében.] Lege Artis Medicinae, 2009, 19(2), 119–126. [Hungarian]

  • 18

    American Psychiatric Association: Diagnostic and statistical manual of mental disorders. American Psychiatric Publishing, Washington, 2000.

  • 19

    Emre, M., Aarsland, D., Brown, R., et al.: Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov. Disord., 2007, 22(12), 1689–1707.

  • 20

    Dubois, B., Burn, D., Goetz, C., et al.: Diagnostic procedures for Parkinson’s disease dementia: recommendations from the Movement Disorder Society Task Force. Mov. Disord., 2007, 22(16), 2314–2324.

  • 21

    Litvan, I., Goldman, J. G., Tröster, A. I., et al.: Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov. Disord., 2012, 27(3), 349–356.

  • 22

    Martinez-Martin, P., Falup-Pecurariu, C., Rodriguez-Blazquez, C., et al.: Dementia associated with Parkinson’s disease: applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat. Disord., 2011, 17(8), 621–624.

  • 23

    Geurtsen, G. J., Hoogland, J., Goldman, J. G., et al.: Parkinson’s disease mild cognitive impairment: application and validation of the criteria. J. Parkinsons Dis., 2014, 4(2), 131–137.

  • 24

    Hobson, P., Meara, J.: Mild cognitive impairment in Parkinson’s disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. Int. J. Geriatr. Psychiatry, 2015 Feb 11. [Epub ahead of print]

  • 25

    Domellöf, M. E., Ekman, U., Forsgren, L., et al.: Cognitive function in the early phase of Parkinson’s disease, a five-year follow-up. Acta Neurol. Scand., 2015 Feb 3. [Epub ahead of print]

  • 26

    Szeto, J. Y., Mowszowski, L., Gilat, M., et al.: Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson’s disease. Parkinsonism Relat. Disord., 2015, 21(1), 31–35.

  • 27

    American Psychiatric Association: Diagnostic and statistical manual of mental disorders. American Psychiatric Publishing, Arlington, 2013.

  • 28

    Kaszás, B., Kovács, N., Balás, I., et al.: Sensitivity and specificity of Addenbrooke’s Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson’s disease. Parkinsonism Relat. Disord., 2012, 18(5), 553–556.

  • 29

    Chou, K. L., Amick, M. M., Brandt, J., et al.: A recommended scale for cognitive screening in clinical trials of Parkinson’s disease. Mov. Disord., 2010, 25(15), 2501–2507.

  • 30

    Feher, E. P., Mahurin, R. K., Doody, R. S., et al.: Establishing the limits of the Mini-Mental State. Examination of ‘subtests’. Arch. Neurol., 1992, 49(1), 87–92.

  • 31

    Nasreddine, Z. S., Phillips, N. A., Bédirian, V., et al.: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc., 2005, 53(4), 695–699.

  • 32

    Volosin, M., Janacsek, K., Németh, D.: Hungarian version of the Montreal Cognitive Assessment (MoCA) for screening mild cognitive impairment. [A Montreal Kognitiv Felmérés (MoCA) magyar nyelvű adaptálása egészséges, enyhe kognitiv zavarban és demenciában szenvedő idős személyek körében.] Psychiatr. Hung., 2013, 28(4), 370–392. [Hungarian]

  • 33

    Gill, D. J., Freshman, A., Blender, J. A., et al.: The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson’s disease. Mov. Disord., 2008, 23(7), 1043–1046.

  • 34

    Kandiah, N., Zhang, A., Cenina, A. R., et al.: Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson’s disease. Parkinsonism Relat. Disord., 2014, 20(11), 1145–1148.

  • 35

    Dalrymple-Alford, J. C., MacAskill, M. R., Nakas, C. T., et al.: The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology, 2010, 75(19), 1717–1725.

  • 36

    Van Steenoven, I., Aarsland, D., Hurtig, H., et al.: Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson’s disease. Mov. Disord., 2014, 29(14), 1809–1815.

  • 37

    Chou, K. L., Lenhart, A., Koeppe, R. A., et al.: Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat. Disord., 2014, 20(10), 1076–1080.

  • 38

    Marras, C., Armstrong, M. J., Meaney, C. A., et al.: Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov. Disord., 2013, 28(5), 626–633.

  • 39

    McColgan, P., Evans, J. R., Breen, D. P., et al.: Addenbrooke’s Cognitive Examination-Revised for mild cognitive impairment in Parkinson’s disease. Mov. Disord., 2012, 27(9), 1173–1177.

  • 40

    Brown, G. G., Rahill, A. A., Gorell, J. M., et al.: Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson’s disease. J. Geriatr. Psychiatry Neurol., 1999, 12(4), 180–188.

  • 41

    Fehér, G., Balás, I., Komoly, S., et al.: Effectiveness of bilateral subthalamic stimulation in the mirror of changes in drug treatment of Parkinson’s disease. [A kétoldali subthalamicus stimuláció hatékonysága az antiparkinson gyógyszerelés változtatásának tükrében.] Ideggyogy. Sz., 2010, 63(9–10), 314–319. [Hungarian]

  • 42

    Kovács, N., Aschermann, Zs., Nagy, F., et al.: Role of deep brain stimulation in the treatment of movement disorders. [Mély agyi stimuláció szerepe a mozgászavarok kezelésében.] Magy. Orv., 2011, 19(7–8), 32–34. [Hungarian]

  • 43

    Pirogovsky, E., Schiehser, D. M., Litvan, I., et al.: The utility of the Mattis Dementia Rating Scale in Parkinson’s disease mild cognitive impairment. Parkinsonism Relat. Disord., 2014, 20(6), 627–631.

  • 44

    Matteau, E., Dupré, N., Langlois, M., et al.: Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia. J. Geriatr. Psychiatry Neurol., 2012, 25(2), 100–106.

  • 45

    Villeneuve, S., Rodrigues-Brazète, J., Joncas, S., et al.: Validity of the Mattis Dementia Rating Scale to detect mild cognitive impairment in Parkinson’s disease and REM sleep behavior disorder. Dement. Geriatr. Cogn. Disord., 2011, 31(3), 210–217.

  • 46

    Schlosser Covell, G. E., Hoffman-Snyder, C. R., Wellik, K. E., et al.: Physical activity level and future risk of mild cognitive impairment or dementia: a critically appraised topic. Neurologist, 2015, 19(3), 89–91.

  • 47

    Scarmeas, N., Luchsinger, J. A., Brickman, A. M., et al.: Physical activity and Alzheimer disease course. Am. J. Geriatr. Psychiatry, 2011, 19(5), 471–481.

  • 48

    Grande, G., Vanacore, N., Maggiore, L., et al.: Physical activity reduces the risk of dementia in mild cognitive impairment subjects: a cohort study. J. Alzheimers Dis., 2014, 39(4), 833–839.

  • 49

    Aarsland, D., Laake, K., Larsen, J. P., et al.: Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry, 2002, 72(6), 708–712.

  • 50

    Kehagia, A. A., Barker, R. A., Robbins, T. W.: Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol., 2010, 9(12), 1200–1213.

  • 51

    Larsson, V., Engedal, K., Aarsland, D., et al.: Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson’s disease dementia. Dement. Geriatr. Cogn. Disord., 2011, 32(4), 227–234.

  • 52

    Rolinski, M., Fox, C., Maidment, I., et al.: Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst. Rev., 2012, 3, CD006504.

  • 53

    Devos, D., Moreau, C., Maltête, D., et al.: Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J. Neurol. Neurosurg. Psychiatry, 2014, 85(6), 668–674.

  • 54

    Kincses, P., Kovács, N., Karádi, K., et al.: Critical issues of the biopsychosocial treatment of Parkinson’s disease. [A Parkinson-kór biopszichoszociális ellátásának kritikus kérdései.] Orv. Hetil., 2015, 156(12), 472–478. [Hungarian]

  • 55

    Langenbahn, D. M., Ashman, T., Cantor, J., et al.: An evidence-based review of cognitive rehabilitation in medical conditions affecting cognitive function. Arch. Phys. Med. Rehabil., 2013, 94(2), 271–286.

  • 56

    Cerasa, A., Quattrone, A.: The effectiveness of cognitive treatment in patients with Parkinson’s disease: a new phase for the neuropsychological rehabilitation. Parkinsonism Relat. Disord., 2015, 21(2), 165.

  • 57

    Reuter, I., Mehnert, S., Sammer, G., et al.: Efficacy of a multimodal cognitive rehabilitation including psychomotor and endurance training in Parkinson’s disease. J. Aging Res., 2012, 2012, 235765.

  • 58

    Kalbe, E., Kessler, J.: Task force WANTED: Many reasons to promote research on cognitive rehabilitation to prevent, delay, and treat cognitive dysfunctions in patients with Parkinson’s disease. Parkinsonism Relat. Disord., 2015, 21(2), 166–167.

 

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

 

Mendeley citation style is available HERE.
  • Impact Factor (2019): 0.497
  • Scimago Journal Rank (2018): 0.176
  • SJR Hirsch-Index (2018): 20
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)
  • Impact Factor (2018): 0.564
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu